Taladegib has been granted orphan drug designation in the U.S. and the European Union as a treatment for idiopathic pulmonary ...

GRI-0621, an experimental oral therapy for IPF, has so far been tolerated well in an ongoing Phase 2 clinical trial.

Columnist Sam Kirton marks four years since his bilateral lung transplant by reflecting on his health, his family, and his ...

Columnist Sam Kirton had to make some adjustments after his IPF diagnosis, but there are still plenty of ways to find joy, he says.

Looking for information on Shallow Breathing (Tachypnea) in pulmonary fibrosis? Read about breathing alterations in IPF here.

Fatigue, sometimes described as overwhelming tiredness or physical malaise, is a common symptom of pulmonary fibrosis (PF) patients. Generally, fatigue is characterized by a lack of energy that does ...

Pulmonary fibrosis (PF) is characterized by the formation of scar tissue in the lungs, which impairs their normal function and makes it harder for oxygen to reach the bloodstream. Despite varying from ...

For pulmonary fibrosis patients, lung transplant is often the best choice for extending life and improving quality of life. Because PF is a progressive disease with no current cure, the lungs ...

There is no cure for pulmonary fibrosis (PF), but many therapies are in the pipeline that may be able to slow disease progression, manage symptoms, and improve quality of life for patients. Some of ...

There is currently no cure for pulmonary fibrosis (PF). However, medication and other treatment options can help improve patients’ quality of life, ease symptoms, and slow the disease’s progression.

In CORAL, 165 IPF patients were given one of three doses of nalbuphine ER to test its ability to reduce cough frequency after six weeks.